Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003539823 | SCV000287349 | uncertain significance | not provided | 2018-05-07 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with EPCAM-related disease. ClinVar contains an entry for this variant (Variation ID: 239124). This variant is present in population databases (rs147494515, ExAC 0.06%). This sequence change replaces serine with leucine at codon 60 of the EPCAM protein (p.Ser60Leu). The serine residue is moderately conserved and there is a large physicochemical difference between serine and leucine. |
Fulgent Genetics, |
RCV000764417 | SCV000895474 | uncertain significance | Congenital diarrhea 5 with tufting enteropathy; Lynch syndrome 8 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002408966 | SCV002716917 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-10-02 | criteria provided, single submitter | clinical testing | The c.179C>T (p.S60L) alteration is located in exon 2 (coding exon 2) of the EPCAM gene. This alteration results from a C to T substitution at nucleotide position 179, causing the serine (S) at amino acid position 60 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |